Reported drug spectrum and disproportionality signals for malignant neoplasm progression in FAERS: a real-world pharmacovigilance study

ObjectiveUsing malignant neoplasm/tumour progression as the endpoint, we screened FAERS for disproportionate reporting signals, characterized the drug spectrum represented in progression-related reports, and prioritized drug–event pairs for further evaluation rather than causal inference.MethodsPublicly available reports from FAERS (2004Q1–2024Q4) and JADER (2004–2024) were analyzed. After FDA-recommended deduplication, malignant tumor progression was identified using the MedDRA Preferred Terms